– Protagonist granted Janssen worldwide rights to PTG-200, a first-in-class, oral peptide IL-23 receptor antagonist
– Deal terms included a $50 million upfront payment and up to an additional $940 million in development and sales milestones; double-digit tiered royalties on net sales
NEWARK, CA, USA I August 24, 2017 I Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced it has closed the worldwide license and collaboration transaction for PTG-200 with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, following termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following closure of the transaction, Protagonist received the upfront payment of $50 million originally announced by the two companies as part of the agreement on May 30, 2017.
The agreement provides Janssen Biotech with a worldwide license for the co-development and commercialization of PTG-200, Protagonist’s first-in-class, oral peptide IL-23 receptor antagonist for all indications including inflammatory bowel disease (IBD). PTG-200 is expected to enter Phase 1 clinical testing before the end of 2017.
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Protagonist’s initial lead peptide product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), consisting primarily of ulcerative colitis and Crohn’s disease.
PTG-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global Phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral Interleukin-23 receptor antagonist for potential treatment of IBD, initially Crohn’s disease, is currently in pre-clinical development and is expected to enter a Phase 1 clinical study in the second half of 2017. The company recently announced it has entered into a worldwide collaboration with Janssen Biotech to co-develop and commercialize PTG-200 for all indications, including IBD.
In addition to PTG-100 and PTG-200, the company is developing an injectable hepcidin mimetic PTG-300 for the treatment of rare diseases such as beta-thalassemia. PTG-300 is currently being studied in a Phase 1 clinical trial.
Protagonist is headquartered in Newark, California with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.
SOURCE: Protagonist Therapeutics
Post Views: 25
– Protagonist granted Janssen worldwide rights to PTG-200, a first-in-class, oral peptide IL-23 receptor antagonist
– Deal terms included a $50 million upfront payment and up to an additional $940 million in development and sales milestones; double-digit tiered royalties on net sales
NEWARK, CA, USA I August 24, 2017 I Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced it has closed the worldwide license and collaboration transaction for PTG-200 with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, following termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following closure of the transaction, Protagonist received the upfront payment of $50 million originally announced by the two companies as part of the agreement on May 30, 2017.
The agreement provides Janssen Biotech with a worldwide license for the co-development and commercialization of PTG-200, Protagonist’s first-in-class, oral peptide IL-23 receptor antagonist for all indications including inflammatory bowel disease (IBD). PTG-200 is expected to enter Phase 1 clinical testing before the end of 2017.
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Protagonist’s initial lead peptide product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), consisting primarily of ulcerative colitis and Crohn’s disease.
PTG-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global Phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral Interleukin-23 receptor antagonist for potential treatment of IBD, initially Crohn’s disease, is currently in pre-clinical development and is expected to enter a Phase 1 clinical study in the second half of 2017. The company recently announced it has entered into a worldwide collaboration with Janssen Biotech to co-develop and commercialize PTG-200 for all indications, including IBD.
In addition to PTG-100 and PTG-200, the company is developing an injectable hepcidin mimetic PTG-300 for the treatment of rare diseases such as beta-thalassemia. PTG-300 is currently being studied in a Phase 1 clinical trial.
Protagonist is headquartered in Newark, California with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.
SOURCE: Protagonist Therapeutics
Post Views: 25
